Skip to content
Biodatica
Start free

Pfizer

Chandler, Arizona

OncologyADCFiled/ApprovedListed · PFE

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Study registered, no phase assigned: Safety And Efficacy Of Bosutinib

1w agoTrial registeredJul 10, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Jan 1, 2027

    HER2-positive Locally Advanced Unresectable, Metastatic Breast Cancer · NOT_YET_RECRUITING · sponsor: Pfizer · A Study to Learn More About Tukysa Once it is Out in the Korean Market

    ClinicalTrials.gov · NCT06873191 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Jul 22, 2026

    Non-small Cell Lung Cancer (NSCLC), Cachexia · NOT_YET_RECRUITING · sponsor: Pfizer · A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Weight Loss

    ClinicalTrials.gov · NCT07663630 (opens the source filing in a new tab)

  3. Trial

    Study registered

    May 18, 2026

    Non-Small Cell Lung Cancer ALK-positive · ACTIVE_NOT_RECRUITING · sponsor: Pfizer · A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

    ClinicalTrials.gov · NCT07556549 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    May 15, 2026

    Advanced Malignancies, Advanced Cancer · RECRUITING · sponsor: Pfizer · An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

    ClinicalTrials.gov · NCT07426757 (opens the source filing in a new tab)

  5. Trial

    Study registered

    May 11, 2026

    Refractory Multiple Myeloma (RRMM) · ACTIVE_NOT_RECRUITING · sponsor: Pfizer · A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan

    ClinicalTrials.gov · NCT07391761 (opens the source filing in a new tab)

  6. Trial

    Study registered

    Apr 20, 2026

    Colorectal Cancer · COMPLETED · sponsor: Pfizer · An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.

    ClinicalTrials.gov · NCT07527832 (opens the source filing in a new tab)

  7. Trial

    PHASE1 registered

    Apr 8, 2026

    Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma · RECRUITING · sponsor: Pfizer · Phase 1 Study of PF-08046033 in Advanced Solid Tumors

    ClinicalTrials.gov · NCT07519655 (opens the source filing in a new tab)

  8. Trial

    PHASE1/PHASE2 registered

    Mar 11, 2026

    Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma · RECRUITING · sponsor: Pfizer · Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

    ClinicalTrials.gov · NCT07421700 (opens the source filing in a new tab)

  9. Trial

    PHASE1/PHASE2 registered

    Feb 10, 2026

    Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell Metastasis, Advanced or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Advanced, Metastatic Renal Cell Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic/Advanced Renal Cell Carcinoma · RECRUITING · sponsor: Pfizer · Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

    ClinicalTrials.gov · NCT07227415 (opens the source filing in a new tab)

  10. Trial

    PHASE3 registered

    Dec 11, 2025

    Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases, Colorectal Neoplasms · RECRUITING · sponsor: Pfizer · Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

    ClinicalTrials.gov · NCT07222800 (opens the source filing in a new tab)

  11. Trial

    PHASE3 registered

    Sep 29, 2025

    Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma · RECRUITING · sponsor: Pfizer · A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

    ClinicalTrials.gov · NCT07144280 (opens the source filing in a new tab)

  12. Trial

    PHASE1 registered

    Sep 22, 2025

    Healthy Adults · COMPLETED · sponsor: Pfizer · A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060

    ClinicalTrials.gov · NCT07160738 (opens the source filing in a new tab)

  13. Trial

    PHASE1 registered

    Aug 20, 2025

    Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer · RECRUITING · sponsor: Pfizer · A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

    ClinicalTrials.gov · NCT07090499 (opens the source filing in a new tab)

  14. Trial

    PHASE3 registered

    Jul 23, 2025

    Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC) · RECRUITING · sponsor: Pfizer · This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

    ClinicalTrials.gov · NCT06758401 (opens the source filing in a new tab)

  15. Trial

    Study registered

    Jul 11, 2025

    Prostate Cancer · ACTIVE_NOT_RECRUITING · sponsor: Pfizer · A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.

    ClinicalTrials.gov · NCT06733337 (opens the source filing in a new tab)

  16. Trial

    Study registered

    Jul 4, 2025

    Carcinoma, Non-Small-Cell Lung · COMPLETED · sponsor: Pfizer · A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

    ClinicalTrials.gov · NCT06678555 (opens the source filing in a new tab)

  17. Trial

    PHASE1/PHASE2 registered

    Jun 30, 2025

    Breast Cancer, Breast Neoplasms · RECRUITING · sponsor: Pfizer · A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

    ClinicalTrials.gov · NCT06966453 (opens the source filing in a new tab)

  18. Trial

    PHASE1 registered

    Nov 11, 2024

    Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Head and Neck Cancer, Colorectal Cancer · TERMINATED · sponsor: Pfizer · A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

    ClinicalTrials.gov · NCT06580938 (opens the source filing in a new tab)

  19. Trial

    Study registered

    Nov 7, 2024

    Acute Lymphocytic Leukemia · ACTIVE_NOT_RECRUITING · sponsor: Pfizer · A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia.

    ClinicalTrials.gov · NCT06476665 (opens the source filing in a new tab)

  20. Trial

    PHASE3 registered

    Oct 22, 2024

    Metastatic Castration-Resistant Prostate Cancer · RECRUITING · sponsor: Pfizer · A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

    ClinicalTrials.gov · NCT06629779 (opens the source filing in a new tab)

  21. Trial

    Study registered

    Sep 30, 2024

    Carcinoma, Non-Small-Cell Lung · WITHDRAWN · sponsor: Pfizer · A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.

    ClinicalTrials.gov · NCT06075615 (opens the source filing in a new tab)

  22. Trial

    Study registered

    May 20, 2024

    Breast Neoplasms · COMPLETED · sponsor: Pfizer · A Study to Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in Australia

    ClinicalTrials.gov · NCT06624020 (opens the source filing in a new tab)

  23. Trial

    PHASE3 registered

    Feb 8, 2024

    Multiple Myeloma · RECRUITING · sponsor: Pfizer · MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

    ClinicalTrials.gov · NCT06152575 (opens the source filing in a new tab)

  24. Trial

    PHASE1/PHASE2 registered

    Jan 10, 2024

    Breast Cancer · ACTIVE_NOT_RECRUITING · sponsor: Pfizer · TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)

    ClinicalTrials.gov · NCT06125522 (opens the source filing in a new tab)

  25. Trial

    Study registered

    Dec 5, 2023

    Acute Myeloid Leukemia · RECRUITING · sponsor: Pfizer · A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia

    ClinicalTrials.gov · NCT05189639 (opens the source filing in a new tab)

  26. Trial

    Study registered

    Oct 6, 2023

    Breast Cancer · COMPLETED · sponsor: Pfizer · A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs

    ClinicalTrials.gov · NCT06003114 (opens the source filing in a new tab)

  27. Trial

    Study registered

    May 22, 2023

    Metastatic ALK+ Non Small Cell Lung Cancer · RECRUITING · sponsor: Pfizer · Post Marketing Surveillance(PMS) Study of Lorviqua in Korea

    ClinicalTrials.gov · NCT05599412 (opens the source filing in a new tab)

  28. Trial

    PHASE4 registered

    Feb 24, 2023

    Acute Lymphoblastic Leukemia · COMPLETED · sponsor: Pfizer · A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

    ClinicalTrials.gov · NCT05687032 (opens the source filing in a new tab)

  29. Trial

    PHASE1 registered

    Feb 20, 2023

    Breast Cancer · COMPLETED · sponsor: Pfizer · A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China

    ClinicalTrials.gov · NCT05732428 (opens the source filing in a new tab)

  30. Trial

    PHASE1 registered

    Nov 30, 2022

    Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Advanced or Metastatic Solid Tumors, HGG, LGG, Low Grade Glioma, High Grade Glioma, Differentiated Thyroid Cancer, NSCLC (Non-small Cell Lung Cancer) · RECRUITING · sponsor: Pfizer · A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

    ClinicalTrials.gov · NCT05538130 (opens the source filing in a new tab)

  31. Trial

    PHASE2 registered

    Jul 11, 2022

    Metastatic Colorectal Cancer · ACTIVE_NOT_RECRUITING · sponsor: Pfizer · A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

    ClinicalTrials.gov · NCT05217446 (opens the source filing in a new tab)

  32. Trial

    PHASE4 registered

    Jul 5, 2022

    Solid Tumors · RECRUITING · sponsor: Pfizer · The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

    ClinicalTrials.gov · NCT05203172 (opens the source filing in a new tab)

  33. Trial

    Study registered

    Apr 20, 2022

    Breast Cancer · COMPLETED · sponsor: Pfizer · Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

    ClinicalTrials.gov · NCT05399329 (opens the source filing in a new tab)

  34. Trial

    PHASE4 registered

    Dec 28, 2021

    Non-Small-Cell Lung Cancer, NSCLC · ACTIVE_NOT_RECRUITING · sponsor: Pfizer · Lorlatinib Continuation Study

    ClinicalTrials.gov · NCT05144997 (opens the source filing in a new tab)

  35. Trial

    PHASE4 registered

    Dec 27, 2021

    NSCLC, ALCL, IMT · ACTIVE_NOT_RECRUITING · sponsor: Pfizer · Crizotinib Continuation Clinical Study

    ClinicalTrials.gov · NCT05160922 (opens the source filing in a new tab)

  36. Trial

    PHASE1 registered

    Aug 18, 2021

    Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer · COMPLETED · sponsor: Pfizer · Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

    ClinicalTrials.gov · NCT04881045 (opens the source filing in a new tab)

  37. Trial

    Study registered

    Jun 11, 2021

    Lung Cancer · COMPLETED · sponsor: Pfizer · Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review

    ClinicalTrials.gov · NCT04609319 (opens the source filing in a new tab)

  38. Trial

    PHASE3 registered

    May 12, 2021

    Prostate Cancer · ACTIVE_NOT_RECRUITING · sponsor: Pfizer · Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

    ClinicalTrials.gov · NCT04821622 (opens the source filing in a new tab)

  39. Trial

    PHASE1 registered

    Mar 17, 2021

    Solid Tumor · TERMINATED · sponsor: Pfizer · PF-07284892 in Participants With Advanced Solid Tumors

    ClinicalTrials.gov · NCT04800822 (opens the source filing in a new tab)

  40. Trial

    Study registered

    Feb 3, 2021

    Breast Cancer · COMPLETED · sponsor: Pfizer · Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

    ClinicalTrials.gov · NCT04735367 (opens the source filing in a new tab)

  41. Trial

    Study registered

    Dec 15, 2020

    Malignant Neoplasm of Breast · RECRUITING · sponsor: Pfizer · Swedish Ibrance Registries Insights (SIRI)

    ClinicalTrials.gov · NCT04654208 (opens the source filing in a new tab)

  42. Trial

    PHASE2 registered

    Nov 16, 2020

    Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer · RECRUITING · sponsor: Pfizer · Study of PF-07248144 in Advanced or Metastatic Solid Tumors

    ClinicalTrials.gov · NCT04606446 (opens the source filing in a new tab)

  43. Trial

    PHASE4 registered

    Sep 29, 2020

    Carcinoma, Non-Small-Cell Lung · COMPLETED · sponsor: Pfizer · Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

    ClinicalTrials.gov · NCT04362072 (opens the source filing in a new tab)

  44. Trial

    PHASE2 registered

    Sep 23, 2020

    Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung · ACTIVE_NOT_RECRUITING · sponsor: Pfizer · Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

    ClinicalTrials.gov · NCT04557449 (opens the source filing in a new tab)

  45. Trial

    PHASE2 registered

    Sep 16, 2020

    Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer · ACTIVE_NOT_RECRUITING · sponsor: Pfizer · PF-07104091 as a Single Agent and in Combination Therapy

    ClinicalTrials.gov · NCT04553133 (opens the source filing in a new tab)

  46. Trial

    Study registered

    Jul 22, 2020

    Non-Small Cell Lung Carcinoma · COMPLETED · sponsor: Pfizer · A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

    ClinicalTrials.gov · NCT06282991 (opens the source filing in a new tab)

  47. Trial

    Study registered

    Oct 25, 2017

    Non-small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Pfizer · Safety and Efficacy of Xalkori ROS1

    ClinicalTrials.gov · NCT03375242 (opens the source filing in a new tab)

  48. Trial

    Study registered

    Feb 1, 2017

    ER/PR(+), Her2(-) Breast Cancer · COMPLETED · sponsor: Pfizer · Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan

    ClinicalTrials.gov · NCT02924584 (opens the source filing in a new tab)

  49. Trial

    Study registered

    Jul 1, 2015

    Chronic Myelogenous Leukemia · COMPLETED · sponsor: Pfizer · Safety And Efficacy Of Bosutinib

    ClinicalTrials.gov · NCT02501330 (opens the source filing in a new tab)

  50. Trial

    Study registered

    Oct 31, 2014

    Metastatic Renal Cell Carcinoma (mRCC) · COMPLETED · sponsor: Pfizer · Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting

    ClinicalTrials.gov · NCT02184416 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources